Replimune Group Stock Market Value
| REPL Stock | USD 7.17 0.01 0.14% |
| Symbol | Replimune |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Replimune 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Replimune's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Replimune.
| 12/03/2025 |
| 03/03/2026 |
If you would invest 0.00 in Replimune on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding Replimune Group or generate 0.0% return on investment in Replimune over 90 days. Replimune is related to or competes with Aprea Therapeutics, Adial Pharmaceuticals, Kiora Pharmaceuticals, Cardio Diagnostics, and Phio Pharmaceuticals. Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer More
Replimune Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Replimune's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Replimune Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 20.74 | |||
| Value At Risk | (6.41) | |||
| Potential Upside | 6.34 |
Replimune Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Replimune's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Replimune's standard deviation. In reality, there are many statistical measures that can use Replimune historical prices to predict the future Replimune's volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.72) | |||
| Treynor Ratio | (0.43) |
Replimune March 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 2.95 | |||
| Coefficient Of Variation | (1,238) | |||
| Standard Deviation | 4.07 | |||
| Variance | 16.6 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.72) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 20.74 | |||
| Value At Risk | (6.41) | |||
| Potential Upside | 6.34 | |||
| Skewness | 0.5594 | |||
| Kurtosis | 1.11 |
Replimune Group Backtested Returns
Replimune Group maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13 % return per unit of risk over the last 3 months. Replimune Group exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Replimune's Risk Adjusted Performance of (0.05), variance of 16.6, and Coefficient Of Variation of (1,238) to confirm the risk estimate we provide. The company holds a Beta of 0.78, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Replimune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Replimune is expected to be smaller as well. At this point, Replimune Group has a negative expected return of -0.52%. Please make sure to check Replimune's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Replimune Group performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.3 |
Weak reverse predictability
Replimune Group has weak reverse predictability. Overlapping area represents the amount of predictability between Replimune time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Replimune Group price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current Replimune price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.3 | |
| Spearman Rank Test | -0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.23 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Replimune Correlation, Replimune Volatility and Replimune Performance module to complement your research on Replimune. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Replimune technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.